Filing search / Inhibrx Biosciences, Inc. / "Research and Development"

8-K

EX-99.1

INBX Inhibrx Biosciences, Inc.

24 May 24

Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi

4:08pm

to the initiation, timing, progress and results of the Company’s research and development programs as well as the Company’s preclinical studies and clinical trials

DEFA14A

INBX Inhibrx Biosciences, Inc.

20 May 24

Additional proxy soliciting materials

9:48pm

materially from such forward looking statements also include but are not limited to the initiation, timing, progress and results of the Company’s research … and development programs as well as the Company’s preclinical studies and clinical trials; the Company’s ability to advance therapeutic candidates

8-K

INBX Inhibrx Biosciences, Inc.

17 May 24

Other Events

5:29pm

but are not limited to the initiation, timing, progress and results of the Company’s research and development programs as well as the Company’s preclinical studies

DEFA14A

INBX Inhibrx Biosciences, Inc.

17 May 24

Additional proxy soliciting materials

4:25pm

from such forward looking statements also include but are not limited to the initiation, timing, progress and results of the Company’s research … and development programs as well as the Company’s preclinical studies and clinical trials; the Company’s ability to advance therapeutic candidates

8-K

EX-99.1

INBX Inhibrx Biosciences, Inc.

9 May 24

Inhibrx Reports First Quarter 2024 Financial Results

4:08pm

. R&D Expense. Research and development expenses were $63.9 million during the first quarter of 2024, compared to $37.4 million during the first quarter … of 2023. The increase in research and development expenses was primarily due to the following factors: ◦an increase in clinical trial expenses

8-K

EX-99.1

awm3yisf

8 May 24

Other Events

4:42pm

DEFM14A

azssjf

26 Apr 24

Proxy related to merger

4:06pm

DEFA14A

zp3nas

12 Mar 24

Additional proxy soliciting materials

4:05pm

8-K

g8epkc69p62vet0

12 Mar 24

Other Events

4:02pm

8-K

EX-99.1

9yu6pnb

28 Feb 24

Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results

9:12am

DEFA14A

dgsg04mlrq5

6 Feb 24

Additional proxy soliciting materials

4:30pm

DEFA14A

mib5afoz

23 Jan 24

Additional proxy soliciting materials

5:25pm

DEFA14A

e8uw08vm

23 Jan 24

Additional proxy soliciting materials

6:38am

8-K

EX-99.1

xwtqo o6r

23 Jan 24

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

6:35am

8-K

v5pq1 xh9jv0b4q5

23 Jan 24

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

6:35am

8-K

EX-2.1

7i6e5qe0

23 Jan 24

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

6:35am

8-K

EX-2.2

hg3ehm55 jjejxs

23 Jan 24

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

6:35am

8-K

EX-99.1

vmke9aqy8c6wa4 7xzg

9 Nov 23

Inhibrx Reports Third Quarter 2023 Financial Results

4:03pm